Medication abortion and family physicians' scope of practice

Journal of the American Board of Family Practice

Volumn 18, Issue 4, 2005, Pages 304-306

  Prine, Linda W ^a   Lesnewski, Ruth ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MIFEPRISTONE; ABORTIVE AGENT;

FAMILY MEDICINE; GENERAL PRACTICE; GENERAL PRACTITIONER; HUMAN; INDUCED ABORTION; MATERNAL CARE; MEDICAL PROFESSION; PREGNANCY; PRIMARY MEDICAL CARE; REVIEW; ARTICLE; ATTITUDE TO HEALTH; CLINICAL PRACTICE; FEMALE; MEDICAL SOCIETY; METHODOLOGY; UNITED STATES;

ABORTIFACIENT AGENTS; ABORTION, INDUCED; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS, FAMILY; PREGNANCY; SOCIETIES, MEDICAL; UNITED STATES;

EID: 26944455628     PISSN: 08938652     EISSN: 15448770     Source Type: Journal    
DOI: 10.3122/jabfm.18.4.304     Document Type: Review

References (28)

1. Alan Guttmacher Institute [homepage on the Internet]. New York: Alan Guttmacher Institute; c2003. [updated 2003 May 7]. State facts about abortion; [about 1 screen]. Available from: http://www.agi-usa.org/pubs/sfaa.html.
2. Finer LB, Henshaw HK. Abortion incidence in the United States in 2000. Perspect Sexual Reprod Health 2003;35:16-24.
3. Lerner S. Abortion's new choice. Village Voice 2000 Oct 4; Features:43-8.
4. Koenig JD, Tapias MD, Hoff T, Stewart FH. Are US health professionals likely to prescribe mifepristone or methotrexate? J Am Med Women's Assoc 2000;55:155-60.
5. Joffe C. Medical abortion in social context. Am J Obstet Gynecol 2000;183:10-5.
6. Henry J. Kaiser Family Foundation. A National Survey: views of women's health care providers on medical abortion. Menlo Park (CA): Kaiser Family Foundation; 2000.
7. Joffe C. Roe v. Wade at 30: What are the prospects for abortion provision. Perspect Sexual Reprod Health 2003;35:29-33.
8. Boonstra H. Mifepristone in the United States: status and future. The Guttmacher Report on Public Policy 2002;5:4-7. Available from http://www.gutt-macher.org/pubs/tgr/05/3/gr050304.html
9. American Academy of Family Physician [homepage on the Internet]. Leawood (KS): American Academy of Family Physicians; c2004 [updated 2005; cited 2004 Aug 13]. AAFP policy and advocacy: family medicine; [about 2 screens]. Available from: http:// www.aafp.org/x6809.xml.
10. Fryer GE, Green LA, Dovey SM, Phillips RI Jr. The United States relies on family physicians unlike any other specialty. Am Fam Physician 2001;63:1669.
11. Henshaw HK, Finer LB. The accessibility of abortion services in the United States, 2001. Perspect Sexual Reprod Health 2003;35:6-15.
12. Westhoff C, Marks F, Rosenfield A. Residency training in contraception, sterilization and abortion. Obstet Gynecol 1993;81:311-4.
13. Grimes DA. Clinicians who provide abortions: the thinning ranks. Obstet Gynecol 1992;80:719-23.
14. Steinauer J, DePinerest T, Robert AM, Wesfall J, Darney P. Training family practice residents in abortion and other reproductive health care: a nationwide survey. Fam Plann Perspect 1997;29:222-7.
15. Gold M, Luks D, Anderson MR. Medical options for early pregnancy termination. Am Fam Physician 1997;56:533-8.
16. Lichtenberg ES, Paul M, Jones H. First trimester surgical abortion practices: a survey of National Abortion Federation members. Contraception 2001; 64:345-52.
17. Approval letter Mifeprex (mifepristone) tablets [letter on the Internet]. Bethesda (MD): Food and Drug Administration; c2000 [posted 2000 Sept 28; cited 2004 Aug 13]. Available from: http://www.fda.gov/ cder/foi/appletter/2000/ 20687appltr.htm.
18. Allen RH, Westhoff C, De Nonno L, Fielding SL, Schaff EA. Curettage after mifepristone-induced abortion: frequency, timing, and indications. Obstet Gynecol 2001;98:101-6.
19. Schaff EA, Stadalius LS, Eisinger SH, Frank P. Vaginal misoprostol administered at home after mifepristone for abortion. J Fam Pract 1997;44:353-60.
20. Prine L, Lesnewski R, Berley N, Gold M. Medical abortion outcomes in four family practices. J Am Board Fam Pract 2003;16:290-5.
21. Newhall EP, Winikoff B. Abortion with mifepristone and misoprostol: regimens, efficacy, acceptability and future directions. Am J Obstet Gynecol 2000; 183 Suppl 2:S44-53.
22. Stewart FH, Shields WC, Hwang AC. Presenting health risks honestly: mifepristone, a case in point. Contraception 2004;69:177-8.
23. Elam-Evans LD, Strauss LT, Herndon J, Parker WY, Whitehead S, Berg CJ. Abortion surveillance-United States, 1999. MMWR Surveill Summ 2002; 51:1-9, 11-28.
24. Chang J, Elam-Evans LD, Berg CJ, et al. Pregnancy-related mortality surveillance-United States, 1991-1999. MMWR Surveill Summ 2003;52:1-14.
25. Morrison H. Sildenafil (Viagra): cardiac risks. CMAJ 2000;163:86-7, 90-1.
26. Wysowski DK, Farinas E, Swartz L. Comparison of reported and expected deaths in sildenafil (Viagra) users. Am J Cardiol 2002;89:1331-4.
27. Egan R, Pomeranz H. Sildenafil (Viagra) associated anterior ischemic optic neuropathy. Arch Opthalmol 2000;118:291-2.
28. Cohen JS. Comparison of FDA reports of patient deaths associated with sildenafil and with injectable alprostadil. Ann Pharmacother 2001;35:285-8.